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Abstract. We have previously reported the specific binding 
of nuclear factor AP-1 isolated from human breast MDA MB 
468 and HeLa cervical tumor cell lines to oligonucleotides 
complementary to three newly elucidated sequences within 
the HIV-1 LTR. These synthesized oligonucleotides, which 
bear high homology to the AP-1 recognition sequence, were 
used in the present study in gel retardation assays together 
with unfractionated nuclear protein extracts from human 
lung, bladder and head and neck tumors and adjacent normal 
tissue to study the role of the AP-1 protein in the regulation 
of HIV-1 expression. We found increased binding of AP-1 to 
these oligonucleotides in 9/12 lung tumors, 9/14 bladder 
tumors and 7/7 head and neck tumors as compared to 
adjacent normal tissues. This confirms previous results 
obtained when using MDA MB 468 and HeLa nuclear 
protein extracts. These results indicate that, AP-1 could be 
contributing to the HIV-1 transcriptional regulation through 
its interaction with the AP-1 binding sites of HIV-1 LTR. 
Introduction 
It is well established that the human immunodeficiency virus 
type 1 (HIV-1) is the main etiologic agent of acquired 
immunodeficiency syndrome (AIDS), which destroys the 
immune surveillance system and thus causes various 
pathological symptoms to develop (1-3). The typical long 
latency before onset of symptoms may be related to various 
stimuli or cofactors, which are involved in the disruption of 
the latent stage of HIV and might lead to provirus 
transcriptional activation. Human and viral proteins (4-6) and 
the oncoprotein ras p21 (7) may contribute to the transition 
Correspondence to: Professor D.A. Spandidos, Institute of 
Biological Research and Biotechnology, National Hellenic 
Research Foundation, 48 Vas. Constantinou Avenue, 116 35 
Athens, Greece 
Key words: lung tumor, bladder tumor, head and neck tumor, AP-1 
activity, HIV-1 LTR sequences 
of HIV-1 from the latent stage to the infectious state. 
Different biological response modifiers (insulin, epidermal 
growth factor, tumor necrosis factor) (8,9), hormones 
(hydrocortisone, dexamethasone) (8) and antitumor drugs 
(ci's-platin, doxorubicin, daunomycin, hexamethylene 
bisacetamide and mitomycin C as opposed to carboplatin) 
(10-16), increase the chloramphenicol acetyl transferase 
expression from the HIV-1 LTR sequence in human and rat 
fibroblasts. 
The human immunodeficiency virus type 1 long terminal 
repeat, HIV-1 LTR, contains binding sites for several cellular 
transcription factors which are implicated in HIV-1 gene 
expression. The regulatory sequences present upstream of the 
transcription initiation site (+1) can be broadly categorized 
into proximal (promoter) and distal (enhancer) elements. The 
promoter element contains the TATA box, located between 
nucleotides -22 to -27, which is presumably recognized by 
the transcription factor TFIID (17). The HIV-1 promoter also 
contains three GC-rich sequences, which bind to the 
ubiquitous transcription factor Spi (17,18). In addition to the 
upstream regulatory sequences, the HIV promoter contains 
several protein-binding sites downstream of the RNA start 
site. A leader binding protein (LBP-1) binds to a region from 
-17 to +27 and TF/NF-1 binds to a sequence from +40 to +45 
(19). Furthermore, the untranslated region of the binding 
protein (UBP-1) has been shown to recognize HIV-1 LTR 
sequences from -13 to +28 of the nucleotide (20). 
The HIV-1 LTR enhancer (-103 to -81) is recognized by 
EBP-1 in resting Τ cells (20) and NF-κΒ (21) and HIVEN 
(22) in activated T-cells. eis elements include the negative 
regulatory element (NRE), located in the region between 
nucleotide positions -357 and -185 relative to the 
transcription initiation site +1. The NRE contains a number 
of recognition sequences for cellular transcription factors 
such as USF, URS and NFAT-1 (6,23), as well as two 
adjacent binding sites for the transcription factor AP-1 which 
are located at nucleotides -348 to -343 and -336 to 331 (24). 
The AP-1 is a family of related transcription factors 
encoded by the members of the jun and fos multigene 
families that have similar binding characteristics and 
sequences (25-30). The AP-1 DNA-complex is composed of 
homo- and heterodimers of the c-fos and c-jun family (31) 
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which dimerize by interdigitation of hydrophobic helices, 
termed leucine-zippers (32). AP-1 can serve as both a 
positive and a negative regulator with respect ta the 
expression of a variety of genes under different conditions. 
The consensus DNA recognition site for AP-1 is 
TGAGTCA (33). Two binding sites for transcription factor 
AP-1 have been mapped within the NRE of HIV-1 LTR (24). 
In our previous study we examined the HIV-1 LTR and 
identified three additional AP-1 binding sites (-516 to -495, 
310 to -287 and +16 to +42) one of which was found within 
the TAR element. In the present study binding of AP-1 to 
these sites has been successfully tested in extracts from lung, 
bladder and head and neck tumors. The AP-1 activity is 
elevated in 9/12 lung tumors, in 9/14 bladder tumors and in 
7/7 head and neck carcinoma tumors as compared to normal 
human tissue. These results are in good agreement with our 
previous study (34) and suggest that these new HIV-1 LTR 
putative AP-1 sites have the same binding effect as nuclear 
extracts from HeLa and MDA MB 468 tumor cell lines. 
LUNG TUMOR 
PROBE : 
PATIENT NO : 
TISSUE : 
AP-1 -*: 
2ab 
Materials and methods 
Preparation of cell extracts. All biopsy material was 
obtained from patients who had undergone lung surgery at 
Metaxa Hospital, Pireas, Greece or bladder and head and 
neck surgery at the University Hospital, Heraklion, Greece. 
The tissue was cut into small pieces and homogenized in 2 ml 
hypotonic buffer (25 mM Tris-HCl pH 7.5, 5 mM KCl, 0.5 
mM MgCl2, 0.5 mM DTT, 0.5 mM PMSF) at 5-10 mg 
protein/ml. The nuclei were pelleted at 2500 rpm in a Sorvall 
SS34 rotor for 10 min at 4°C. The pellets were washed 3 
times with 2 ml isotonic buffer (25 mM Tris-Cl pH 7.5, 5 
mM KCl, 0.5 mM MgCl2, 0.1 M sucrose, 0.5 mM DTT, 1 
mM PMSF), resuspended in nuclei extraction buffer (25 mM 
Tris-Cl pH 7.5, 1 mM EDTA, 0.1% NP40, 0.5 mM DTT, 0.5 
mM PMSF) and were further clarified after centrifugation at 
25000 rpm in a Beckman Ti 50 rotor for 60 min at 4°C. The 
supernatant was removed and the extracts were stored at -70°C. 
Protein estimation was performed as described by Bradford 
(35). 
Preparation of double stranded oligonucleotides and 
retardation assays. DNA oligonucleotides were as described 
(34). The oligonucleotides were purified as described (34) 
and the double stranded oligonucleotides were 5' end-labelled 
using γ32Ρ-ΑΤΡ and T4 polynucleotide kinase and end filled 
using the Klenow fragment of DNA polymerase according to 
Maniatis et al (36). 
Results 
Four short DNA regions which are putative AP-1 binding 
sites were identified in the HIV-1 LTR (34). From these four 
sequences, region 2 shows the highest homology (85.8%) to 
the AP-1 consensus (5'-TGAGTCA-3') and therefore the 
corresponding oligonucleotide hybrid 2ab was used in our 
previous studies to test the affinity of the AP-1 protein in 
MDA MB 468 and HeLa tumor cells. In the present study the 
same oligonucleotide sequence was used to examine the 
presence of AP-1 activity in lung, bladder and head and neck 
Figure 1. Electrophoretic mobility shift analysis using 2ab-AP-l binding 
consensus oligonucleotide. 20(K) cpm y32P-oligo were mixed with 20 μg of 
nuclear extracts from lung tumors, lymph nodes and adjacent normal tissues 
and HeLa cells. The DNA-AP-1 protein complex is indicated by the arrow. 
Ν = normal, Τ = tumor, L = lymph nodes. 
tumors and adjacent normal tissue. Nuclear extracts were 
mixed with γ 3 2 Ρ -end labelled double stranded oligo­
nucleotides E3AP-1 and 2ab, respectively and analyzing the 
formation of DNA-protein complexes by gel retardation 
assays. Twelve lung tumors were analysed and eight of them 
showed elevated levels of AP-1 activity as compared with 
either the adjacent normal tissue or the correspoding lymph 
nodes (Fig. 1). The same oligonucleotide hybrid, 2ab, was 
also used to test the presense of AP-1 activity in bladder and 
head and neck tumors. Nine out of fourteen bladder tumors 
tested showed elevated levels of AP-1 activity as compared 
to adjacent normal tissue (Fig. 2). Seven head and neck 
tumors seven tumors were analysed and all of them showed 
elevated AP-1 as compared with adjacent normal tissues 
(Fig. 3). A comparison of the data on the AP-1 activity and 
the pTNM in lung, bladder and head and neck tumors are 
shown in Tables I, II and III. 
Having established that most of the examined lung and 
bladder tumors and all of the head and neck tumors had 
elevated AP-1 activity, we subsequently confirmed that the 
remaining non-tested AP-1-like sites (lab,4ab) on HIV-1 
LTR are functional. This was tested by employing nuclear 
extracts from lung tumor No 12 and bladder tumor No 1, 
mixed with a y32P-end labelled 2ab or lab oligonucleotide 
hybrids and employing the non-labelled oligonucleotide 
hybrids as competitors lab, 2ab, 3ab, 4ab, E3AP-1 and 
analysing the formation of DNA-protein complexes by gel 
retardation assays. As shown in Figs. 4 (lung tumor) and 5 
(bladder tumor) the non-labelled oligonucleotide hybrids 
E3AP-1, lab, 2ab and 4ab competed with the labelled 
oligonucleotide hybrid 2ab for DNA-AP-1 protein complex 
formation. Also as shown in Fig. 6 (lung tumor) the non-
labelled oligonucleotide hybrids lab, 2ab and E3AP-1 
competed with the labelled oligonucleotide hybrid lab for 
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PROBE : 
PATIENT NO : 
TISSUE : 
BLADDER TUMOR 
2ab 
1 
Ν Τ 
2 3 
Ν Τ Ν Τ 
Ν 
4 
τ Ι 
Table I. ρΤΝΜ, AP-1 level and stage of differentiation in 
tumors of lung cancer patients. 
AP-1 -» 
FREE 
DNA 
Figure 2. Electrophorelic mobility shift analysis using 2ab-AP-l binding 
consensus oligonucleotide. 20(K) cpm y32P-oligo was mixed with 20 [lg of 
nuclear extracts from bladder tumors and adjacent normal tissues. The 
DNA-AP-1 protein complex is indicated by the arrow. Ν = normal, Τ = 
tumor. 
HEAD AND NECK CARCINOMA TUMORS 
PROBE 
PATIENT 
No 
TISSUE 
a. < 
LU 
1 
Τ 
1 
Ν Τ 
2 
Ν Τ 
2ab 
3 4 
Ν Τ Ν Τ 
5 
Ν Τ 
6 
Ν Τ 
Ι 
Ι 
7 
Ν Τ 
FREE 
ΟΝΑ 
Figure 3. Electrophoretic mobility shift analysis using Ε,ΑΡ-l and 2ab-AP-l 
binding consensus oligonucleotide. Nuclear extracts from head and neck 
carcinomas were incubated with Y32P-end-labelled Ε,ΑΡ-l and 2ab-AP-l 
oligonucleotide hybrids (lanes 1 and 2-15, respectively). The DNA-AP-1 
protein complex is indicated by the arrow. Ν = normal, Τ = tumor. 
DNA-AP-1 protein complex formation. This is not surprising 
since EjAP-1 contains the AP-1 binding consensus from the 
E3 promoter (37), while lab and 4ab are highly homologous 
(71.5%) to the same sequence (34). However, the non-
Patient Noa 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
pTNMb 
T3N,M0 
T2N,M0 
T2N0M0 
T2N0M0 
T,N0M0 
T3N2M0 
T2N2M0 
T4N2M0 
T2N,M0 
T2NoM0 
T2NoM0 
T2N,M0 
AP-1 level0 
elevated 
elevated 
non-elevated 
elevated 
non-elevated 
elevated 
elevated 
elevated 
elevated 
non-elevated 
elevated 
elevated 
Stage of 
differentiation 
III 
II 
I 
III 
I 
III 
III 
II 
II 
I 
II 
III 
"All tissue specimens were obtained from lung cancer patients. 
bpTNM was defined according to the UICC classification. 
Tumor/adjacent normal tissue. 
Table II. pTNM, AP-1 level and stage of differentiation in 
tumors of bladder cancer patients. 
Patient Noa 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12. 
13 
14 
pTNMb 
T3N0M0 
T0N0M0 
T2N0M0 
T3N0M0 
T3N0M0 
T,N0M0 
T0N0M0 
T0N0M0 
Τ,ΝοΜο 
T0N0M0 
T2N0M0 
T0N0M0 
T,N0M0 
T2N0M0 
AP-1 level0 
elevated 
non-elevated 
elevated 
elevated 
elevated 
elevated 
non-elevated 
non-elevated 
elevated 
non-elevated 
elevated 
non-elevated 
elevated 
elevated 
Stage of 
differentiation 
III 
I 
11 
III 
III 
II 
I 
I 
11 
I 
11 
I 
11 
II 
aAll tissue specimens were obtained from bladder cancer patients. 
bpTNM was defined according to the UICC classification. 
Tumor/adjacent normal tissue. 
labelled oligonucleotide hybrid 3ab did not compete for AP-1 
binding activity with the labelled oligonucleotide hybrids 2ab 
and lab, presumably because it shares only a limited 
homology (57.1%) to the AP-1 concensus. 
The non-labelled oligonucleotide hybrids E3AP-1, lab, 
2ab and 4ab competed with the labelled oligonucleotide 
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Table III. pTNM, AP-1 level and stage of differentiation of 
head and neck tumors. 
BLADDER TUMOR 
Patient Noa 
1 
2 
3 
4 
5 
6 
7 
pTNMb 
T3NoM0 
T3N,M0 
T2N2M0 
T3N,M0 
T2N0M0 
T2NoM0 
T2N0M0 
AP-1 level0 
elevated 
elevated 
elevated 
elevated 
elevated 
elevated 
elevated 
Stage of 
differentiation 
II 
III 
IV 
III 
II 
II 
II 
aAll tissue specimens were obtained from head and neck cancer 
patients. bpTNM was defined according to the UICC classification. 
Tumor/adjacent normal tissue. 
LUNG TUMOR 
COMPETITOR 
PROBE : 
AP-1 -» 
•Q •& -9 -9 co co Μ Ξ 
CM τ - CO ^ J 
FREE 
DNA 
LANE 1 2 
Figure 4. Effect of competitor sequences on gel electrophoretic mobility 
shift. Nuclear extracts from lung tumors were incubated with y32P-end 
labelled E3AP-1 and 2ab-AP-l oligonucleotide hybrids, respectively (lanes 1 
and 2-7). In competition assays, 200-fold excess of cold competitor 
oligonucleotides 2ab, lab, 3ab, 4ab and E,AP-1 (lanes 3-6 and 7, 
respectively), were incubated with the nuclear extracts before adding the 
probe. The DNA-AP-1 protein complex is indicated by the arrow. 
E3AP-I for DNA-AP-1 protein complex formation (Fig. 7, 
lung tumor). In Fig. 8 the effect of JUN antibody on the 
formation of the DNA-protein complex between E3AP-1 or 
2ab oligo and the AP-1 protein from bladder tumor nuclear 
extracts is shown. 
COMPETITOR : 
PROBE : h A P 1 1 
Λ .α -Q -9 
co CO « « 
CM f- CO ·"* 
2ab 
; ; I -A 
AP-1 -» 
FREE 
DNA 
LANE 
Figure 5. Effect of competitor sequences on gel electrophoretic mobility 
shift. Nuclear extracts from bladder tumors were incubated with y32P-end 
labelled E,AP-1 and 2ab-AP-l oligonucleotide hybrids, respectively (lanes 1 
and 2-7). In competition assays, 200-fold excess of cold competitor 
oligonucleotides 2ab, lab, 3ab, 4ab and E3AP-1 (lanes 3-7) were incubated 
with the nuclear extracts before adding the probe. The DNA-AP-1 protein 
complex is indicated by the arrow. 
Discussion 
The human immunodeficiency virus type 1 long terminal 
repeat, HIV-1 LTR, contains binding sites for several cellular 
transcription factors which contribute to HIV-1 gene 
expression. The interaction between cellular and viral 
proteins and DNA sequences of the HIV-1 LTR is proposed 
to play a crucial role in transactivating HIV-1 and in 
inducing the switch from latency to virus production and 
phenotypic appearance of cytopathic effects. 
A number of studies have indicated that the AP-1 site is 
an important component of several regulatory regions. 
Functionally important AP-1 sites have been identified in the 
enhancer of the chicken ß-globin (38), metallothionein Ha 
(39) and collagenase genes (40); in the Polyomavirus 
enhancer (41), and in the human ß-globin dominant control 
region (42). Furthermore, AP-1 binding sites have also been 
identified in the genome of the visna virus closely related to 
HIV-1 where they play a critical role in basal activity and 
transactivation of the viral LTR by the virally encoded TAT 
protein (43). 
In a previous study we identified three newly elucidated 
AP-1 binding sites in the HIV-1 LTR using in gel retardation 
assays nuclear extracts from MDA MB 468 and HeLa tumor 
cells (34). In the present study we examined the gel mobility 
shift assays with the same synthetic oligonucleotides 
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COMPETITOR 
PROBE 
PATIENT TISSUE 
ΓΓ" -Q -9 % (0 CO m 
- ™ CM UJ 
I lab Ì 
Ι Ν I Lung Tumor 
BLADDER TUMOR 
AP-1 -» 
FREE 
DNA 
LANE 
Figure 6. Effect of competitor sequences on gel electrophoretic mobility 
shift. Nuclear extracts from lung tumors and adjacent normal tissues (lanes 
2-6 and 1, respectively), were incubated with Y32P-end labelled lab-AP-1 
oligonucleotide hybrid. In competition assays, 200-fold excess of cold 
competitor oligonucleotides lab, 2ab, E3AP-1 and 3ab (lanes 3-6), were 
incubated with the nuclear extracts before adding the probe. Only the 
specific retarded bands of interest are shown. 
LUNG TUMOR 
COMPETITOR : 
PROBE : 
ANTIBODY - z: 
3 
3 
- 3 
PROBE E3AP1 2ab 
— Β 
E3AP1 
LANE 
Figure 8. Effect of JUN antibody on the AP-1/oligonucleotide complexes 
studied by gel electrophoretic mobility shift assays. Nuclear extracts from 
bladder tumors were incubated with E3AP-1 oligonucleotide (lane 1) and 
2ab oligonucleotide (lane 3). JUN antibody and nuclear extracts from 
bladder tumors were incubated with E3AP-1 oligonucleotide (lane 2) and 
2ab oligonucleotide (lane 4), respectively. The shift in the mobility of the 
JUN complex is shown. 
AP-1 -» 
Figure 7. Effect of competitor sequences on gel electrophoretic mobility 
shift. Nuclear extracts from lung tumors were incubated with y32P-end 
labelled E3AP-1 oligonucleotide hybrid. In competition assays, 200-fold 
excess of cold competitor oligonucleotides E3AP-1 lab, 2ab and 4ab (lanes 
2-5) were incubated with the nuclear extracts before adding the probe. Only 
the specific retarded bands of interest are shown. 
containing the putative HIV-1 LTR AP-1 sites and nuclear 
extracts from human lung, bladder and head and neck 
tumors. Several studies have suggested that AP-1 activity 
may be important in cell regulation and growth (44,45). In 
the present study we report that AP-1 activity is elevated in 
75% of lung tumors, 66.6% of bladder tumors and in 100% 
of head and neck carcinomas examined as compared to 
adjacent normal tissue. These and other results (46-48) 
suggest that the products of jun and fos oncogenes represent 
a class of inducible cellular proteins that could modulate the 
expression of genes containing AP-1 binding sites since 
previous studies have demonstrated that there is elevated 
expression of the oncogenes Η-ras and K-ras in the 
development of squamous cell carcinoma of the head and 
neck (49,50). It is therefore plausible that the increased levels 
of AP-1 we have observed in breast, bladder, lung,and head 
and neck human tumors (47-51) are due to ras activation 
which triggers fos (52) and JUN/AP-1 (53) gene expression. 
Therefore, it would be of interest to examine whether a 
correlation between ras, jun and fos expression and tumor 
stage exists. 
A comparision of AP-1 activity and pTNM was carried 
out for lung, bladder and head and neck tumors (Table I, II 
and III) as described previously in studies for human lung 
and bladder tumors (48). Although the number of samples 
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analysed was relatively small, a correlation was found 
between the stage of differentiation and AP-1 levels in head 
and neck tumors. The higher the stage of differentiation the 
higher the AP-1 levels (48). 
The importance of AP-1 in the regulation of HIV-1 gene 
expression can only be speculated on. Many agents that 
induce transcription of latent, proviral DNA or reporter gene 
linked to the HIV-1 LTR (6-16) also induce a substantial 
level of fos expression (54,55). Although no causal link 
between these two phenomena has been demonstrated it is 
possible that AP-1 family proteins which represent a class of 
induc ib le ce l lu lar p r o t e i n s could play a role in the 
transcriptional regulation of human immunodeficiency virus 
type 1 gene expression. 
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